ponsegromab

Scale consists of five items, each rated 0-4. Total score ranges from 0 (minimum) to 20 (maximum). Higher scores are associated with a better outcome.

Body weight was measured in kilograms using a calibrated weighing scale. Baseline was defined as the last average of the duplicate measurements prior to, or on Day 1. The average of the duplicate body weights collected at assessment time was considered. The posterior medians and 90 percent (%) credible intervals (5th and 95th percentiles of the relevant posterior distribution) were reported for each randomized dose (including placebo). 4-Parameter maximal effect (E max) model: change from baseline = E 0 + (E max \* dose\^Hill) / (ED 50\^Hill + dose\^Hill), where E0 is the placebo effect, E max is the maximum effect, ED 50 is the dose producing 50% of the maximum effect, and Hill is the slope parameter. Model utilized a Bayesian methodology with a robustified, informative meta-analytic predictive prior for the placebo change from baseline at week 12.

Assessed by computer tomography (CT) (or MRI \[magnetic resonance imaging\])

AUCinf was defined as area under the serum concentration-time profile from time 0 extrapolated to infinite time.

AUClast was defined as area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration.

Cmax was defined as maximum observed concentration. Cmax was observed directly from data.

Tmax was defined as time for Cmax. Tmax was observed directly from data as time of first occurrence.

t1/2 was defined as terminal half life. t1/2 was calculated as Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration time curve.